Table 4.

Adverse events of grade 1 or higher experienced by at least 5% of patients

	IGF-1R-positive soft-tissue sarcoma (n=57)		IGF-1R-positive bone sarcoma (n=54)		IGF-1R-negative sarcoma (n=63)
	Grade 1–2	Grade 3–4	Grade 1–2	Grade 3–4	Grade 1–2	Grade 3–4
Abdominal pain	6 (11%)	2 (4%)	0	1 (2%)	9 (14%)	0
Activated partial thromboplastin time prolonged	4 (7%)	1 (2%)	5 (9%)	1 (2%)	8 (13%)	2 (3%)
Alanine aminotransferase increased	18 (32%)	0	19 (35%)	0	18 (29%)	1 (2%)
Alkaline phosphatase increased	16 (28%)	0	18 (33%)	1 (2%)	19 (30%)	1 (2%)
Allergic rhinitis	3 (5%)	0	2 (4%)	0	7 (11%)	0
Alopecia	6 (11%)	0	4 (7%)	0	5 (8%)	0
Anaemia	22 (39%)	7 (12%)	29 (54%)	4 (7%)	42 (67%)	5 (8%)
Anorexia	24 (42%)	0	17 (31%)	0	26 (41%)	1 (2%)
Anxiety	4 (7%)	0	3 (6%)	0	8 (13%)	0
Arthralgia	1 (2%)	0	5 (9%)	0	4 (6%)	0
Aspartate aminotransferase increased	17 (30%)	1 (2%)	14 (26%)	0	17 (27%)	1 (2%)
Back pain	10 (18%)	1 (2%)	6 (11%)	1 (2%)	14 (22%)	0
Bruising	3 (5%)	0	2 (4%)	0	4 (6%)	0
Chest wall pain	4 (7%)	0	4 (7%)	0	6 (10%)	0
Cholesterol high	4 (7%)	1 (2%)	3 (6%)	0	3 (5%)	0
Constipation	20 (35%)	0	18 (33%)	0	25 (40%)	0
Cough	12 (21%)	1 (2%)	11 (20%)	1 (2%)	20 (32%)	0
Creatine increased	13 (23%)	1 (2%)	16 (30%)	0	15 (24%)	0
Dehydration	6 (11%)	0	2 (4%)	1 (2%)	8 (13%)	1 (2%)
Depression	5 (9%)	0	8 (15%)	0	5 (8%)	0
Diarrhoea	18 (32%)	2 (4%)	14 (26%)	1 (2%)	26 (41%)	6 (10%)
Dizziness	4 (7%)	0	4 (7%)	0	5 (8%)	0
Dry mouth	3 (5%)	0	5 (9%)	0	8 (13%)	0
Dry skin	14 (25%)	0	11 (20%)	0	9 (14%)	0
Dysgeusia	9 (16%)	0	9 (17%)	0	18 (29%)	0
Dyspnoea	15 (26%)	0	11 (20%)	1 (2%)	19 (30%)	2 (3%)
Epistaxis	11 (19%)	0	9 (17%)	0	14 (22%)	0
Fatigue	30 (53%)	3 (5%)	35 (65%)	2 (4%)	43 (68%)	1 (2%)
Fever	11 (19%)	1 (2%)	6 (11%)	1 (2%)	10 (16%)	0
Flu-like symptoms	4 (7%)	0	1 (2%)	0	3 (5%)	0
Gastro-oesophageal reflux disease	2 (4%)	0	0	0	7 (11%)	0
Generalised muscle weakness	3 (5%)	0	1 (2%)	0	3 (5%)	0
Headache	11 (19%)	0	13 (24%)	0	15 (24%)	0
Hypercalcaemia	7 (12%)	0	4 (7%)	0	4 (6%)	0
Hyperglycaemia	28 (49%)	7 (12%)	35 (65%)	4 (7%)	38 (60%)	7 (11%)
Hyperkalaemia	2 (4%)	1 (2%)	1 (2%)	0	9 (14%)	0
Hypernatraemia	2 (4%)	1 (2%)	1 (2%)	0	8 (13%)	0
Hypertriglyceridaemia	19 (33%)	4 (7%)	24 (44%)	2 (4%)	26 (41%)	2 (3%)
Hypoalbuminaemia	15 (26%)	1 (2%)	13 (24%)	0	16 (25%)	0
Hypocalcaemia	10 (18%)	0	7 (13%)	1 (2%)	12 (19%)	2 (3%)
Hypoglycaemia	3 (5%)	0	4 (7%)	0	2 (3%)	0
Hypokalaemia	12 (21%)	2 (4%)	7 (13%)	1 (2%)	11 (17%)	1 (2%)
Hyponatraemia	10 (18%)	2 (4%)	14 (26%)	0	19 (30%)	2 (3%)
Hypophosphataemia	5 (9%)	5 (9%)	7 (13%)	4 (7%)	5 (8%)	7 (11%)
Hypotension	3 (5%)	0	1 (2%)	1 (2%)	3 (5%)	0
International normalised ratio increased	3 (5%)	1 (2%)	4 (7%)	0	3 (5%)	1 (2%)
Insomnia	3 (5%)	0	6 (11%)	0	11 (17%)	0
Leucopenia	23 (40%)	3 (5%)	24 (44%)	2 (4%)	28 (44%)	4 (6%)
Limb oedema	7 (12%)	0	3 (6%)	0	9 (14%)	1 (2%)
Lymphocytopenia	8 (14%)	9 (16%)	6 (11%)	7 (13%)	13 (21%)	9 (14%)
Musculoskeletal and connective tissue disorder—other	2 (4%)	0	1 (2%)	0	6 (10%)	0
Myalgia	8 (14%)	0	8 (15%)	0	7 (11%)	0
Nail infection	3 (5%)	0	0	0	5 (8%)	0
Nail ridging	2 (4%)	0	2 (4%)	0	4 (6%)	0
Nasal congestion	2 (4%)	0	6 (11%)	0	5 (8%)	0
Nausea	20 (35%)	0	20 (37%)	0	24 (38%)	0
Neutropenia	8 (14%)	2 (4%)	13 (24%)	5 (9%)	13 (21%)	4 (6%)
Non-cardiac chest pain	3 (5%)	0	3 (6%)	2 (4%)	2 (3%)	0
Oral mucositis	36 (63%)	5 (9%)	27 (50%)	9 (17%)	42 (67%)	5 (8%)
Pain	20 (35%)	2 (4%)	22 (41%)	1 (2%)	26 (41%)	0
Papulopustular rash	5 (9%)	1 (2%)	2 (4%)	0	2 (3%)	0
Paraesthesia	2 (4%)	0	2 (4%)	0	5 (8%)	0
Paronychia	4 (7%)	0	3 (6%)	0	3 (5%)	0
Peripheral sensory neuropathy	5 (9%)	0	7 (13%)	0	9 (14%)	0
Pruritus	11 (19%)	0	5 (9%)	0	12 (19%)	0
Rash acneiform	2 (4%)	0	13 (24%)	0	12 (19%)	0
Rash maculopapular	12 (21%)	2 (4%)	12 (22%)	0	16 (25%)	0
Sinusitis	2 (4%)	0	1 (2%)	0	5 (8%)	0
Skin infection	4 (7%)	0	3 (6%)	0	6 (10%)	0
Sore throat	6 (11%)	0	4 (7%)	0	6 (10%)	0
Upper respiratory infection	2 (4%)	0	2 (4%)	0	5 (8%)	0
Urinary tract infection	5 (9%)	2 (4%)	1 (2%)	1 (2%)	3 (5%)	1 (2%)
Thrombocytopenia	30 (53%)	3 (5%)	30 (56%)	7 (13%)	32 (51%)	9 (14%)
Vomiting	15 (26%)	1 (2%)	13 (24%)	0	14 (22%)	0
Weight loss	10 (18%)	0	9 (17%)	0	21 (33%)	1 (2%)
Total	712	75	675	62	945	77

Data are number (%).